Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study
Steger, G; Petru, E; Haslbauer, F; Egle, D; Galid, A; Sliwa, T; Lang, A; Kuhr, T; Petzer, A; Ruckser, R; Mlineritsch, B; Greil, R; Seifert, M; Singer, C; Andel, J; Kwasny, W; Marth, C; Pichler, P; Tinchon, C; Bartsch, R ANN ONCOL. 2016; 27:
An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer
Winder, T; Posch, F; Asamer, E; Stotz, M; Siebenhuner, A; Schlick, K; Magnes, T; Samaras, P; Szkandera, J; Clavien, PA; Neureiter, D; Greil, R; Pestalozzi, BC; Stoeger, H; Gerger, A; Egle, A; Pichler, M ANN ONCOL. 2016; 27:
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
Scheithauer, W; Prager, G; Greil, R; Mlineritsch, B; Schaberl-Moser, R; Gerger, A; Langle, F; Viragos-Toth, I; Andel, J; Pichler, A; Pecherstorfer, M; Kretschmer, A; Seebacher, A; Jagdt, B; Eisterer, W; Krippl, P ANN ONCOL. 2016; 27:
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)
Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Mlineritsch, B; Greil, R ANN ONCOL. 2016; 27:
Targeting tumor metabolism in the therapy of aggressive squamous cell carcinoma in patients with epidermolysis bullosa
Welponer, T; Hofbauer, JP; Gruber, C; Kienzl, M; Aminzadeh-Gohari, S; Feichtinger, R; Lang, R; Bauer, JW; Kofler, B; Reichelt, J MELANOMA RES. 2016; 26: E77-E77.
Evaluation of the immunogenicity of viral epitopes in a cancer immunogene therapy approach for squamous cell carcinoma in RDEB
Reichl, VM; Kienzl, M; Stocklinger, A; Tockner, B; Reichelt, J; Gruber, C; Pinon-Hofbauer, J MELANOMA RES. 2016; 26: E107-E107.
Developing a cancer immunogene therapy approach for Epidermolysis bullosa-associated squamous cell carcinoma
Kienzl, M; Leb-Reichl, V; Stoecklinger, A; Tockner, B; Gratz, IK; Bauer, JW; Reichelt, J; Gruber, C; Hofbauer, JP J INVEST DERMATOL. 2016; 136(9): S242-S242.
Combining antisense molecules with splicing modulation for KRT14 repair in epidermolysis bullosa
Liemberger, B; Arzt, C; Hainzl, S; Hofbauer, JP; Wally, V; Murauer, EM; Bauer, JW; Reichelt, J; Koller, U J INVEST DERMATOL. 2016; 136(9): S189-S189.
OUTCOME OF PATIENTS WITH REFRACTORY OR RELAPSED AML WITH IDH1 AND IDH2 MUTATIONS AFTER CONVENTIONAL SALVAGE THERAPY: A STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP (AMLSG)
Paschka, P; Schlenk, R; Weber, D; Horst, HA; Ringhoffer, M; Khone, CH; Held, G; Kundgen, A; Gotze, K; Brossart, P; Greil, R; Lubbert, M; Wattad, M; Rummel, MJ; Heuser, M; Gaidzik, VI; Teleanu, V; Thol, F; Gohring, G; Ganser, A; Dohner, K; Dohner, H HAEMATOLOGICA. 2016; 101: 326-326.
CD49D EXPRESSION IMPACTS ON THE IBRUTINIB-INDUCED LYMPHOCYTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A ROLE OF BCR-MEDIATED INSIDE-OUT VLA-4 INTEGRIN ACTIVATION
Tissino, E; Caldana, C; Benedetti, D; Herman, SE; ten Hacken, E; Rossi, FM; Dal Bo, M; Bulian, P; Bomben, R; Zaja, F; Chiarenza, A; Sklar, LA; Hartmann, TN; Chigaev, A; Burger, JA; Del Poeta, G; Wiestner, A; Gattei, V; Zucchetto, A HAEMATOLOGICA. 2016; 101: 49-50.